S&P Futures
4,158.50+3.00(+0.07%)Dow Futures
33,970.00+12.00(+0.04%)Nasdaq Futures
13,913.00+15.75(+0.11%)
Syneos Health, Inc. (SYNH)
- Simply Wall St.
Here's Why I Think Syneos Health (NASDAQ:SYNH) Might Deserve Your Attention Today
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
- Insider Monkey
Is SYNH Stock A Buy or Sell?
The Insider Monkey team has completed processing the quarterly 13F filings for the December quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
- GlobeNewswire
Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021
MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET. Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on April 29, 2021. About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast. Investor Relations Contact:Ronnie SpeightSenior Vice President, Investor Relations+1 919 745 2745Investor.Relations@syneoshealth.com Press/Media Contact:Gary GatyasExecutive Director, External Communications+1 908 763 3428gary.gatyas@syneoshealth.com
